Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Parsol 1789 safety/effectiveness with some Category I sunscreens established -- FDA.

This article was originally published in The Tan Sheet

Executive Summary

PARSOL 1789 SAFETY/EFFECTIVENESS WITH CATEGORY I SUNSCREENS ESTABLISHED, FDA concluded in a May 9 letter to King & Spalding attorney Edward Basile. In response to the March 2, 1993 citizen petition filed by Basile on behalf on Givaudan-Roure, FDA said it would allow use of UVA blocker Parsol 1789 (avobenzone) 2%-3% in combination with some Category I sunscreen ingredients. The petition is now being handled by Givaudan-Roure sister company Hoffmann-La Roche.

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS085446

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel